anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
RATIONALE AND OBJECTIVES: To develop a fully automated deep-learning (DL) model using digital radiography (DR) with relatively high accuracy for predicting the efficacy of non-vascularized fibular grafting (NVFG) and identifying suitable patients for this procedure.
MATERIALS AND METHODS: A retrospective analysis was conducted on osteonecrosis of femoral head patients who underwent NVFG between June 2009 and June 2021. All patients underwent standard preoperative anteroposterior (AP) and frog-lateral (FL) DR. Subsequently, the radiographs were pre-processed and labeled based on the follow-up results. The dataset was randomly divided into training and testing datasets. The DL-based prediction model was developed in the training dataset and its diagnostic performance was evaluated using the testing dataset.
RESULTS: A total of 339 patients with 432 hips were included in this study, with a hip preservation success rate of 71.52% as of June 2023. The hips were randomly divided into a training dataset (n = 324) and a testing dataset (n = 108). The ensemble model in predicting the efficacy of NVFG, reaching an accuracy of 78.9%, a precision of 78.7%, a recall of 96.0%, a F1-score of 86.5%, and an area under the curve (AUC) of 0.780. FL views (AUC, 0.71) exhibited better performance compared to AP views (AUC, 0.66).
CONCLUSION: The proposed DL model using DR enables automatic and efficient prediction of NVFG efficacy without additional clinical and financial burden. It can be seamlessly integrated into various clinical scenarios, serving as a practical tool to identify suitable patients for NVFG.
Obesity is associated with an impairment in postprandial glucose disposal, which is an important risk factor for type 2 diabetes (T2D). Weight loss improves postprandial glycemic control. The difficulty in achieving successful weight loss by using lifestyle therapy (diet and physical activity) has led to an increased interest in bariatric surgery, which is the most effective available weight loss therapy. Moreover, bariatric surgery procedures that bypass the upper gastrointestinal tract, such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), have profound effects on glycemic control and cause remission in a large percentage of people with T2D. However, the effect of RYGB and SG surgery on postprandial glucose disposal among key metabolic organs has not been investigated and compared. The goal of this study is to provide a comprehensive evaluation of whole-body and tissue-specific glucose metabolism after consuming a mixed meal in lean people and people with obesity, before and after 20-35% weight loss induced by RYGB or SG surgery. Glucose uptake (GU) will be assessed by using: i) a combination of oral and intravenous stable isotopically-labeled glucose tracers to assess the delivery of ingested glucose into the systemic circulation and whole-body glucose disposal rate; and ii) positron emission tomography (PET) with magnetic resonance (MR) imaging to assess muscle, subcutaneous and visceral adipose tissue, liver, small intestine, and pancreas GU.
Introduction and Objectives: the use of corticosteroids in patients with severe community pneumonia, bacterial infection which kills lots of patients around the world, reduces morbimortality. However, to our knowledge, there are no studies with steroids for patients in intensive care with nosocomial pneumonia, among which those with ventilator associated pneumonia, infections which carry a high mortality rate. The treatment for those diseases involves intensive care and antibiotics, but there is a need for inexpensive, adjuvant therapies which improve the outcome for those patients. Therefore, the objective of this study is to compare hydrocortisone versus placebo, both with standard therapy, in the outcome of critical care patients diagnosed with nosocomial pneumonia.

Methods: multicenter randomized, open-label, controlled trial, with two parallel groups: hydrocortisone or placebo, associated with nosocomial pneumonia's standard treatment. Patients with viral or other etiologies of pneumonia will be excluded, as well as corticosteroids chronical users, or patients with conditions which demand this type of therapy. Intravenous 100mg of hydrocortisone and normal saline (the placebo) will be tested every eight hours for five days or until intensive care unit (ICU) discharge or until the patient dies. The sample will be of 180 patients, 90 in each group, in different ICUs in Brazil. The primary outcome will be early clinical failure between the third and seventh days of the patient's inclusion in the study. The secondary outcomes will be survival and mortality in both groups, need for intubation, mechanical ventilation, vasoactive drugs and dialysis, lengths of stay in the hospital and in the ICU and radiological progression. Moreover, we will analyze adverse events and there will be a safety interim analysis when 25% of the whole sample is recruited, which may interrupt the study in case of a high frequency of such events (\> 15% grade 3 or 4 as defined by the FDA). Finally, we will conduct an efficacy interim analysis when 50% of the sample is recruited. The study will be interrupted only if there is a statistical significant difference regarding the primary outcome with p \< 0.001 (Haybittle-Peto criteria).

Discussion, risks, and benefits: this will be the first multicenter randomized trial to test hydrocortisone plus standard therapy in critical care patients with nosocomial pneumonia. This intervention is inexpensive and may improve the outcome of those patients, besides having an acceptable side effects profile. Weighing the benefits and risks of this study, as well as its strengths and potential weaknesses, it is believed that its realization is justified, in addition to bringing important advances in the field of intensive care.
PURPOSE: A composition containing TAZ for muscle differentiation and/or regeneration is provided to activate MyoD-dependent myogenic gene transcription. CONSTITUTION: A composition containing TAZ for inducing myocyte differentiation contains TAZ polypeptides as an active ingredient. The polypeptide contains an amino acid sequence of sequence number 1. The polypeptide contains an amino acid sequence of sequence number 2. The composition contains a gene encoding TAZ polypeptide as an active ingredient. The gene contains a base sequence of sequence number 3 or 4.
The objective of the proposed study is to develop an innovative, friend-based motivational interview (FMI) that encourages and prepares friends to reduce sexual assault (SA) risk. Delivered to pairs of friends (dyads), the FMI will be designed to foster collaborative efforts to increase readiness for, and decrease barriers to helping behavior, and to teach and plan together for assault prevention skills. As the role of alcohol has been under-addressed in SA prevention efforts, the FMI also will explicitly attend to how intoxication may serve as a barrier to friend intervention, and strategies for overcoming this barrier. The completion of this project's aims will yield a novel intervention that capitalizes on the natural resource of women's friendships to decrease risk for sexual assault - a pervasive public health problem affecting a substantial portion of young adult women in the U.S.

Twenty-four friend dyads will participate in the friend-based motivational interview (FMI) along with 24 wait-list control dyads (total of 48 dyads). The study will compare groups on outcomes at post-intervention and at bi-weekly 3 month follow-ups, and also examine within participant change. The study will focus on whether effects are in the expected direction and whether the strength of effect sizes are of practical magnitude. It is expected that participants receiving the FMI will demonstrate significant increases in readiness, and engagement in friend assault prevention behavioral skills (FAPBs), and demonstrate decreases in perceived barriers, at post-intervention and over the 3-month follow-up. Follow-up data will be utilized to provide a rich description of the role of alcohol in implementing FAPBs, and whether the FMI reduces the impact of alcohol use. In exploratory analyses, it will be examined whether the intervention may be associated with decreased assault risk, as well as decreased drinking.
Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 1000-2000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
1,135,966. Sustained-release medicaments. CESKOSLOVENSKA AKADEMIE VED. 6 Jan., 1967 [6 Jan., 1966; 9 Jan., 1966], No. 832/67. Headings A5B and A5R. Pharmaceutical preparations for the sustained administration of a medicament to a living organism in direct contact therewith comprise a hydrogel of a polymer which is insoluble but swellable in the fluids of the living organism and which is prepared by copolymerising a hydrophilic mono-olefinic monomer with 0.1 to 5% of a cross-linking agent which surrounds, or in which is incorporated, a soluble biologically active substance which is diffusible through the hydrogel. Forms of preparation mentioned include inplants, prostheses, granules, and delayed release forms (in which the polymer may be an ionexchanger which binds the medicament). Suitable polymers are those derived from such monomers as ethylene glycol monomethacrylate, ethylene glycol monoacrylate, their polyethylene glycol and poly-ethylene glycol/ propylene glycol analogues, methacrylamide, acrylamide, maleic acid anhydride, methacrylic acid, acrylic acid, alkali metal ethylene sulphonate and mixtures thereof. Numerous types of medicament are mentioned, specific examples relating to preparations comprising chloramphenical (microporous sponge for treating burns). 1-γ-oxabutyl-2,5-dioxo-3,4-diphenyl pyrazolidine (implant tablets), tetracycline hydrochloride (sponge), hormones e.g. dihydrocortisone and ovarial or androgenic hormones and 6-azauridine (films) and oxytetracycline (implant).
Assessment of body composition is an essential aspect of veterinary canine care, particularly as prevalence of overweight and obesity in dogs is increasing. Few quantitative objective methods for body composition measurement are available for routine clinical use. Bioelectrical impedance analysis is widely used in human medicine and nutritional assessment and although it has shown promise in production animals it has not yet been adopted for companion animals. The present study validated bioimpedance spectroscopy (BIS) against the reference method of dual-energy X-ray absorptiometry. Resistivity coefficients for use in BIS were determined: ρe = 444.8 and ρi = 1477.8 ohm.cm and used to predict fat-free mass (FFM) in a cohort of 35 mixed breed dogs. Overall, FFM was predicted to within 3.5% of reference values. At an individual level, FFM was predicted within 2 standard deviations (95% confidence) of 10%. BIS provides an objective quantitative alternative to the widely used semi-quantitative body condition scoring. In addition, BIS provides estimates of body water volumes (total, extra-and intracellular), information that can be useful in fluid management. BIS is inexpensive, and simple to perform but does require brief (<5 min) sedation of the animal.
COVID-19 infection during pregnancy is associated with increased risk of pre-eclampsia, preterm birth and stillbirth. Pregnant people with COVID-19 have a higher rate of ICU admission and intubation than those who are not pregnant. COVID-19 vaccine is recommended before pregnancy and during pregnancy to decrease these risks. Despite the benefits of COVID-19 vaccination, only 71% of pregnant women were vaccinated for COVID-19 as of June 2022 (most prior to pregnancy), with a much lower rate of 58% among non-Hispanic Black women. An effective intervention is needed to improve COVID-19 vaccination rates for pregnant people overall.

Lack of vaccination stems from a combination of patient (lack of knowledge, vaccine hesitancy), provider (suboptimal communication skills, missed opportunities), and system (e.g. lack of standing orders and patient reminders) factors. An effective intervention is needed to improve COVID-19 vaccination rates for pregnant people. To address this, the investigators plan to use a clustered RCT (randomizing practices), allocating half of the participating practice sites within each health system to the VAX-MOM COVID-19 intervention and the other half to standard of care. The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
The invention comprises two grain conditioners. The first grain conditioner, which is suitable for use on all grains, comprises a pectinase, a protease, a beta-glucanase and an amylase. The second grain conditioner, which is designed for use on easier-to-digest grains, comprises a pectinase, a beta-glucanase, an amylase and a hemicellulase. The invention also comprises animal feeds which comprise a grain which has been conditioned with one of the grain conditioners of the invention designed to be effective on that grain and methods of increasing the weight gain and feed utilization efficiency of an animal comprising feeding the novel animal feeds of the invention to the animal. The invention further comprises a method of conditioning a grain which comprises providing the grain, contacting the grain with one of the grain conditioners of the invention designed to be effective on that grain and incubating the grain and grain conditioner together for at least about 30 minutes. Finally, there is also provided another method of conditioning a grain comprising providing the grain, scarifying the grain, contacting the grain with one of the grain conditioners of the invention designed to be effective on that grain and incubating the grain and grain conditioner for at least about 30 minutes.
Prepare suspension at time of dispensing as follows: Tap bottle until all powder flows freely. Add approximately 1/3 of the total amount of water for reconstitution (see table below) and shake vigorously to wet powder. Add remainder of the water and again shake vigorously.

  


NOTE: SHAKE ORAL SUSPENSION WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration preferable, but not required.
Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
Pregnant girls/young women 15-24 years living with HIV (new, previously diagnosed, and transfers) receiving PMTCT services in routine healthcare randomized to the intervention between 01st January and 30th June 2026 and followed up for at least one year to 30th June 2027. While the specific intervention will developed earlier in the project, it may include a package of evidence-based approaches such as peer mentor mothers, male partner involvement, flexible hours for girls/young women and mobile phone reminders. A focal team of 2-3 persons will be trained and engaged to drive the implementation of the interventions at randomized faciltiies. The focal team will orient and engage other staff and stakeholders to deliver the interventions, identify and address gaps, and monitor implementation fidelity and quality using standard operating procedures.
PURPOSE:A complex substance of an extract of tea leaf comprising (-) epigallocatechingallate as a main component and active aluminum hydroxide. CONSTITUTION:Tea leaves are extracted with warm water or a hydrophilic organic solvent, washed with chloroform, the extracted component is dissolved in an organic solvent, the solvent is distilled away, the extract is dried, to give an extract of tea leaves comprising (-)epigallocatechingallate(EGCg) as a main component. Further, the extract is subjected to high performance liquid chromatography using reversed phase dispersion column partition chromatography to separate EGCg. It is dissolved in a hydrophilic solvent, preferably water. On the other hand, an alkali solution is added to an aqueous solution of aluminum chloride, etc., to give active aluminum hydroxide as a gelatinous water suspension, which is blended with the extract of tea leaves or an aqueous solution of EGCg, stirred, allowed to stand for 24hr to give a complex substance. It has antiulcer action, anti-pepsin action and acid control ling action and has improved effect and safety as a remedy for peptic ulcer.
In a pharmacodynamic (PD) trial conducted in 47 patients, the PD and safety profiles were similar for PROAIR RESPICLICK and ProAir HFA. Comparable changes from baseline in the PD measures (serum glucose and potassium concentrations, QTcB, QTcF, heart rate, systolic blood pressure, and diastolic blood pressure) were observed following cumulative dose administration up to 1440 mcg of both PROAIR RESPICLICK and ProAir HFA. The overall safety, efficacy and PD profile of PROAIR RESPICLICK and ProAir HFA were comparable.

Following 90 or 180 mcg single-dose inhalation, the bronchodilatory effect of PROAIR RESPICLICK was significantly greater than placebo and comparable to that of ProAir HFA in patients 12 years of age and older (N=71) and pediatric patients 4 to 11 years of age (N=61) with persistent asthma.

Cardiac Electrophysiology

As with other beta2-adrenergic agonists, PROAIR RESPICLICK prolonged QT intervals following a 1440 mcg cumulative dose. The prolongation was comparable to that of ProAir HFA.
BACKGROUND: Low back pain (LBP) is a highly prevalent condition that comprise a large portion of outpatient practice, challenging the diagnosis and treatment. However, the diagnostic tools are limited to clinical history, physical examination and imaging. Degenerative disc disease (DDD) is a significant cause of LBP, and emerging literature confirms the elevated levels of biomarkers in the discs. These biomarkers may serve as a tool for diagnosis, but may also be useful in predicting the treatment outcome. Here, we examine the expression of various cytokines on 1-year recovery from patients with LBP.
METHODS: Patient-reported outcome (PRO) in terms of pain intensity (VAS), disability (ODI), and quality of life (Eq-5D) is collected from 44 patients at baseline and 12 months after surgery to study the influence of baseline TNF-α, IL-1β, and IL-6 mRNA expression in both annulus fibrosus (AF) and nucleus pulposus (NP).
RESULTS: Between baseline and follow-up, our cohort showed improvement in VAS back pain (p < 0.001), VAS leg pain (p < 0.001), ODI (p = 0.02), and Eq-5D (p = 0.01). Baseline levels of IL-1 β was positively correlated with VAS back pain scores in AF (p = 0.05) and NP (p = 0.01) at 1-year follow-up. TNF-α expression at baseline was also positively correlated to ODI scores (p = 0.01) at follow-up and inversely correlated to improvements in ODI score between baseline and follow-up, suggesting that high TNF-α expression at baseline is associated with poor outcomes from surgery.
CONCLUSION: The results from our study support that TNF-α expression at baseline can serve as a very important predictor of treatment response from lumbar fusion surgery.
Current antidepressant therapy shows substantial limitations, and there is an urgent need for the development of new treatment strategies for depression. Stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis play an important role in the pathogenesis of depression. HPA axis activity is self-regulated by negative feedback at several levels including adrenocorticotropic hormone (ACTH)-mediated feedback. Here, we investigated whether noncorticotropic synthetic analogs of the ACTH(4-10) fragment, ACTH(4-7)-Pro-Gly-Pro (Semax) and Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]ACTH(4-10)-NH2 (Melanotan II (MTII), a potent agonist of melanocortin receptors), have potential antidepressant activity in a chronic unpredictable stress (CUS) rat model of depression. Stressed and control male adult Sprague-Dawley rats received daily intraperitoneal injections of saline or a low dose (60 nmol/kg of body weight (BW)) of Semax or MTII. Rats were monitored for BW and hedonic status, as measured in the sucrose preference test. We found that chronic treatment with Semax and MTII reversed or substantially attenuated CUS-induced anhedonia, BW gain suppression, adrenal hypertrophy and a decrease in the hippocampal levels of BDNF. In the forced swim test, no effects of the CUS procedure or peptides on the duration of rat immobility were detected. Our findings show that in the CUS paradigm, systemically administered ACTH(4-10) analogs Semax and MTII exert antidepressant-like effects on anhedonia and hippocampal BDNF levels, and attenuate markers of chronic stress load, at least in male rats. The results support the argument that ACTH(4-10) analogs and other noncorticotropic melanocortins may have promising therapeutic potential for the treatment and prevention of depression and other stress-related pathologies.
Children whose families signed consent form will be included. Height and weight will be measured. Then they will be taken to the balance measurements. Design will firstly be shown to child and one trial will be permitted before starting the test. Timed-up and Go test will also be used as a reliable and valid test for dynamic balance in this age group. Single leg standing will also be used to investigate the discrimination feature of the dynamic balance tested by new design platform.

All tests will be done without socks and shoes. Timing will be the only results for all tests. Calibrated chronometers will be used for this aim. After all measurements complete, statistical analysis will be conducted.
Medicaments contain one or more active ingredients of formula (I) (where Y is 0, 1, 2 or 3). (I) have bactericidal and haemostyptic props., and a selective tanning effect on pathologically altered tissue. They may be used in veterinary medicine, esp. in veterinary gynaecology and obstetrics, and in human medicine in the treatment of non-specific vaginal flux and Trichomonas infections. Despite the low Ph of aq. soln. of (I), their use does not lead to adverse effects on healthy tissue, while necrotic material is removed. (I) stimulate the healing process and lead to the coagulation of inflamed tissue. Pref. dosage forms are those for local application.